



Simplifying HCV Screening and Treatment: Care in Nonspecialty Settings

HCV Screening



HCV Treatment



AASLD, American Association for the Study of Liver Diseases; AE, adverse event; CBC, complete blood count; CMP, comprehensive metabolic panel; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FIB-4, fibrosis-4; HAV, hepatitis A antibody; HBc, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBs, hepatitis B surface antibody; HCV, hepatitis C virus; INR, international normalized ratio; POC, point-of-care; TDF, tenofovir disoproxil fumarate.

AASLD-Recommended Regimens for Simplified HCV Treatment

Glecaprevir/pibrentasvir

Dose
3 tablets by mouth once daily

Administration
Take with food

Duration
8 weeks

Sofosbuvir/velpatasvir

Dose
1 tablet by mouth once daily

Administration
Take with or without food

Duration
12 weeks

Additional Comments
For people with cirrhosis and genotype 3, baseline NS5A RAS testing is required; if without Y93H, can receive this treatment

Assess for drug-drug interactions

hep-druginteractions.org/checker

HCV/HIV Coinfection

- Consult for treatment guidance
- Patient eligible for AASLD Simplified Treatment unless receiving TDF or with eGFR <60 mL/min

References

AASLD HCV Simplified HCV Treatment Guidelines. December 2023.

Glecaprevir/pibrentasvir PI.

Sofosbuvir/velpatasvir PI.

CCO

powered by CEA

Learn more at:

www.clinicaloptions.com/2025HCVStreetMedicineProgram